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Using recombinant antibodies functionally expressed by
secretion to the periplasm in Escherichia coli as a model
system, we identified mutations located in turns of the
protein which reduce the formation of aggregates during
in vivo folding or which influence cell stability during
expression. Unexpectedly, the two effects are based on
different mutations and could be separated, but both
mutations act synergistically in vivo. Neither mutation
increases the thermodynamic stability in vitro. However,
the in vivo folding mutation correlates with the yield of
oxidative folding in vitro, which is limited by the side
reaction of aggregation. The in vivo folding data also
correlate with the rate and activation entropy of thermally
induced aggregation. This analysis shows that it is possible
to engineer improved frameworks for semi-synthetic anti-
body libraries which may be important in maintaining
library diversity. Moreover, limitations in recombinant
protein expression can be overcome by single amino acid
substitutions.
Key words: E.colifF(ab) and Fv fragments/protein engineering/
protein expression/protein folding
Introduction
Folding in vivo can be the limiting process in the production of
many recombinant proteins. It has been shown that aggregation
during in vivo and in vitro folding is a specific off-pathway
process involving folding intermediates (Jaenicke, 1987;
Wetzel, 1994). For a few proteins it has been possible to
isolate point mutations which induce or suppress aggregation
(Tsai et al, 1991; Jappelli et al, 1992; Mitraki and King,
1992; Chrunyk and Wetzel, 1993; Chrunyk et al., 1993; Dale
et al, 1994), and the solution of this problem may offer the
possibility of improving production of industrially important
proteins (Mitraki and King, 1992). We undertook an investi-
gation of the molecular basis of this limitation using recombin-
ant antibody fragments secreted into the periplasmic space of
Escherichia coli as a model system. This class of structurally
well characterized p"-barrel proteins offers an almost unlimited
database of proteins which have similar sequence and structure
but have been found to fold in E.coli in rather different
proportions.
The efficient expression of antibody fragments in bacteria
is clearly of great technological importance. The routinely
achievable amounts of recombinantly expressed antibody will
be decisive for the viability of this technology for many
medical and technological applications. In this paper we show
that there are two principal factors which are limiting the
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expression yields. The first can be directly related to folding
problems of the antibody fragments in the periplasmic space
of E.coli, and the second is a consequence of the stress imposed
by the antibody on the bacterial cell secreting it. In its mildest
form it leads to periplasmic leakiness and then to lysis with
the occasionally observed plasmid loss; in severe cases it leads
to plasmid rearrangements and loss of clones from libraries.
Since such problems are not universally observed for high-
level secretion of proteins in E.coli, it follows that they are a
consequence of the antibody sequence and structure. Here we
describe experiments that have helped us to analyze and solve
some of these problems.
While many expression experiments of antibody fragments
in bacteria have now been reported (Pluckthun, 1994), a
comparison of functional yields is made essentially impossible
by the use of many different vector systems, strains, experi-
mental conditions and types of antibody fragment. Moreover,
results from high cell density experiments are occasionally
directly compared with shake-flask experiments; however, this
is not useful for drawing conclusions about the components
of the expression system. Here we analyze the expression of
different antibody fragments under identical conditions and
show that the single most important factor is the primary
sequence of the antibody variable domains. We then show that
the crucial features within the sequence can be elucidated and
that it is possible to engineer an antibody of mediocre expres-
sion behavior into one of superior properties without interfering
with its binding properties.
The basis for our study was the conclusion derived from
previous work that it is the periplasmic folding process
itself which limits the whole expression process (Skerra and
PlUckthun, 1991; Knappik et al, 1993). This suggestion was
based on the observations that (i) substantial amounts of
periplasmic, correctly processed, albeit insoluble, protein were
formed and (ii) increased overproduction of total protein was
easily achieved but led to only very modest increases in soluble
processed protein. Only small amounts of soluble precursor
could be detected when a strong promoter was used. It is
likely that the precursor would be stable enough to observe it
if it were present in large amounts, since it has been seen in
certain mutants (Glockshuber et al, 1992). The fact that high-
level production leads to the formation of insoluble protein is
also observed with many other proteins (Shatzman, 1990), and
the high achievable amounts of total protein show that the
levels, production rates and degradation rates of plasmid,
mRNA and protein are not the primary culprits of low
yields of functional protein, although they may of course be
contributing factors. Furthermore, the observation of processed,
insoluble protein suggests that the protein does not have a
problem in transport through the membrane, since it has
apparently come into contact with the signal peptidase on the
periplasmic face of the inner membrane. Taken together, it
appears that a side reaction of folding, namely aggregation,
limits the yield in vivo. In this paper we show that the
in vitro folding yields under oxidative folding conditions of
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the antibody mutants constructed and examined do correlate
directly with the soluble expression yields in vivo.
In previous work we have also investigated the effect of
external catalysis on the antibody fragments folding in the
periplasm (Knappik et al., 1993). While the antibody fragments
absolutely require the E.coli disulfide-forming protein DsbA
in vivo, its overexpression does not increase the yield for any
fragment tested. This suggests that DsbA plays an active role
in the folding process but is not limiting under the conditions
examined. Similarly, the overexpression of proline-cis-trans-
isomerase (PPIase) had only a marginal effect on the yield of
one of the fragments. The aggregation processes appear,
therefore, to occur before the action of these proteins, or at
least to be independent of their action.
Periplasmic folding, and in particular the question of peri-
plasmic chaperones, have been reviewed recently (Wtllfing and
PlUckthun, 1994a). While indirect evidence for the existence of
a periplasmic chaperone was obtained (Wiilfing and PlUckthun,
1994b), the efficiency of this system is still unclear. It appears
that the most effective strategy to obtain high-yield folding of
periplasmic proteins is to engineer the protein itself. Here we
propose that the crucial determinants are loops in the structure,
at least in P-barrel proteins.
Materials and methods
Materials and strains
For all cloning and expression experiments the E.coli K12
strain JM83 [ara (lac-pro AB) rpsL (strA) thi ((J)80 lacZAM 15),
Yanisch-Perron et al., 1985] was used. The plasmid pAK19
(Carter et al., 1992) was obtained from P.Carter (Genentech,
South San Francisco, CA).
Construction of plasmids
All in vivo experiments were carried out in the pHJ series of
vectors (Knappik et al., 1993; Knappik and PlUckthun, 1994).
They were constructed from our previous vectors (Skerra and
PlUckthun, 1991; Knappik et al., 1993) and contain unique
restriction sites at the 5' and 3' ends of the antibody genes,
facilitating subcloning of antibody genes and domain shuffling
between the F(ab)—, Fv- and single-chain Fv- vectors (Knappik
and PlUckthun, 1994; A.Knappik, unpublished data). Addition-
ally, both genes for the heavy and the light chains carry
short versions of the FLAG™ tag (Prickett et al., 1989; Knappik
and PlUckthun, 1994) attached to the N-terminus of the mature
protein to allow detection of the chains in immunoblots,
regardless of the particular antibody fragment expressed. The
genes of the huMab4D5 antibody (Carter et al., 1992) were
inserted in the pHJ vectors by PCR amplifying the coding
regions of the variable and the constant domains independently
using the vector pAK19 as a template.
The mutant antibody fragments H1-H10 were constructed
by site-directed mutagenesis (Kunkel et al., 1987) using the
vector pLisc_SE (Knappik et al., 1993) as a single-stranded
template and up to six oligonucleotides per reaction. After
screening and sequencing, the mutated part of the gene was
gel-purified and ligated into the respective vector. Mutant HI 1
was constructed by combining the mutations HI and H3;
mutant HI2 was constructed by removing the P40A mutation
in mutant H10. Complementarity-determining region (CDR)
grafting of the CDRs of McPC603 onto the huMab4D5
framework was carried out by the recursive PCR gene synthesis
protocol described by Prodromou and Pearl (1992). All con-
structs were verified by DNA sequencing.
Monitoring cell stability during expression
Growth curves and leakiness data were obtained as follows.
20 ml of LB medium containing 100 u.g/ml ampicillin and 25
(ig/ml streptomycin were inoculated with an E.coli JM83
overnight culture harboring the plasmid encoding the respective
antibody fragment and incubated at room temperature (24°C)
until an OD550 of 0.5 was reached. IPTG was added to a final
concentration of 1 raM and the incubation was continued for
several hours. Every 30-60 min after induction the OD550 was
measured. At the same time, 100 |il of the culture were
removed and the cells pelleted by centrifugation (4 min at
6000 r.p.m.). In the supernatant, the P-lactamase activity was
measured (O'Callaghan et al., 1972) to quantify the degree of
cell leakiness. After 3 h of induction, an aliquot of the culture
was removed and the cells were lysed (see below). The p-
lactamase activity in the cell extract was measured to verify
that differences in the P-lactamase activity in the medium
were not due to differences in the total amount of p-lactamase.
The total amount of P-lactamase was found to deviate by
—20% between the clones in repeated experiments.
Cell lysis and immunoblotting
Cell cultures harboring the plasmids encoding the respective
antibody Fv fragments were grown and induced (see above).
After 3 h of induction, 2-5 ml of the cultures, depending on
the OD550, were harvested by centrifugation and lysed using
a modified protocol given by Wetzel et al. (1991). The cell
pellets (normalized to the same OD550) were frozen for at least
1 h at -20°C and lysed by the addition of 500 |il lysis buffer
(10 mM glycylglycine, 1 mM EDTA, 2 M urea, pH 7.5) to
the frozen cells, and incubated on ice until thawed (20 min).
5 (xl hen-egg lysozyme (250 u,g) were added and the suspension
was incubated for 10 min at room temperature. After adding
20 ^1 of 100 mM MgCl2 and 10 u.1 of DNase I (1 mg/ml) and
a further incubation of 10 min at room temperature, the lysates
were centrifuged (5 min at 14 000 r.p.m.) and the supernatants
containing the soluble fractions were withdrawn. The pellets
were shaken at 4°C in 535 \x\ lysis buffer until resuspended
to give the insoluble fractions. This procedure was chosen
because it gave the same distribution of soluble and insoluble
antibody fragments as lysing the cells with a French press,
which was used for preparative antibody expression. The P~
lactamase activity was measured in all fractions. The fractions
were assayed by reducing SDS-PAGE with the samples
normalized to the same p-lactamase activity to account for
differences in plasmid copy number as well as cell leakiness.
After blotting and immunostaining the gel using the anti-
FLAG antibody Ml (Prickett et al., 1989) as the first antibody,
an Fc-specific anti-mouse antiserum conjugated to horseradish
peroxidase as second antibody and a chemoluminescent detec-
tion assay as described elsewhere (Ge et al., 1994), the lanes
were scanned and quantitated by laser densitometry. All
experiments were carried out at least in duplicate.
Thermodynamic stability
Fv fragments were purified using phosphorylcholine-
Sepharose affinity chromatography (Skerra and PlUckthun,
1988). The concentration was estimated photometrically using
an extinction coefficient calculated according to Gill and
von Hippel (1989). Equilibrium denaturation curves were
obtained by denaturing 0.1 |iM protein in borate buffered
saline/phosphorylcholine (BBS/PC) buffer (200 mM sodium
tetraborate, pH 8.0, 160 mM NaCl, containing 5 mM phos-
phorylcholine) and increasing amounts of urea (0.0-6.8 M
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urea in 36 steps) in a total volume of 1.8 ml. After incubating
the samples for 15 h at 10°C, the fluorescence spectra were
recorded at 10°C from 300 to 400 nm with an excitation
wavelength of 280 nm. The emission wavelength of the
fluorescence peak shifted from 331.4 to 348.3 nm during
denaturation (maximal deviation in repeated measurements
0.3 nm) and was used as the dependent variable. The denatura-
tion was found to be reversible (data not shown). The data
were fitted according to Pace (1990), assuming a two-state
equilibrium system, since the fluorescence of the Fv fragment
of McPC603 is dominated largely by VH (>90%), which
contains four Trp and nine Tyr, compared with one Tip and
five Tyr in VL (Glockshuber et al., 1992). The 'fraction
unfolded' was calculated from the fit values using the equation:
apparent rate constant
using the equation:
F =
was calculated by fitting the data
Fv = [yf + (m{ • [D]) - y]/[(yf + mf • [D]) - (yu [D])],
where yf is the y intercept for the native conformation, ya is
the y intercept for the unfolded conformation, ntf is the slope
of the pre-transition baseline, mu is the slope of the post-
transition baseline and [D] is the denaturant concentration.
The parameters were obtained by fitting the data according to
Pace (1990).
Renaturation kinetics
Purified Fv fragments were denatured for at least 3 h at 10°C
in either BBS/PC (200 mM sodium tetraborate, 160 mM NaCl,
5 mM phosphorylcholine, pH 8.0) containing 7 M urea
(denaturation under oxidized conditions) or BBS/PC containing
7 M urea and 100 mM dithioerythreitol (denaturation under
reducing conditions). The denatured protein was diluted 90-
fold in a cuvette containing refolding buffer (BBS/PC for
refolding of the oxidized protein or BBS/PC containing 5 mM
oxidized glutathione for refolding of the reduced protein),
leading to a final protein concentration of 0.11 |iM. During
refolding, the solution was maintained at 10°C and mixed with
a magnetic stirrer. Refolding was monitored for 3 h by scanning
the fluorescence every 90 s from 300 to 400 nm (excitation
wavelength: 280 nm). The data were analyzed by two methods:
(i) the peak-shift from 348.3 to 331.4 nm during refolding
was calculated by the estimation of the maximum emission
wavelength of every scan. These data indicate the time-course
of folding into a 'native-like' structure, where 'native-like' is
defined by the property of having an emission maximum of
-331.4 nm; and (ii) the fluorescence intensities at 331.4 nm
were estimated from the scans. These values represent the
yield of the folding process, assuming that a decrease in
fluorescence intensity at 331.4 nm during refolding monitors
aggregation or loss by adsorption to the cuvette while an
increase in fluorescence at that wavelength monitors the
conversion into the folded protein.
Thermal denaturation
For measuring the thermal denaturation, 20 |il of purified Fv
fragments were diluted into a cuvette containing 1.78 ml of
BBS/PC buffer (200 mM sodium tetraborate, 160 mM NaCl,
5 mM phosphorylcholine, pH 8.0), prewarmed to the respective
temperature and stirred with a magnetic stirrer. The final
protein concentration was carefully adjusted to 1.0 (iM in all
experiments and for all mutants. The time-course of formation
of aggregates was monitored with a fluorescence spectrometer
(Shimadzu, RF-5000) at an excitation/emission wavelength
of 400 nm. The kinetics of aggregation were found to be
concentration-dependent and followed a pseudo-first-order
reaction at the chosen protein concentration of 1.0 (J.M. The
where t is the time, f0 is the apparent starting time-point of
aggregation, and F and F(00] are the emission values at the
time-points t and f(oo), respectively.
Results
Development of the analysis system
We chose a model system consisting of the murine anti-
phosphorylcholine antibody McPC6O3 (Satow et al., 1986;
Skerra and PlUckthun, 1988) and the humanized version of
the anti-HER2 antibody 4D5 (Carter et al., 1992; Eigenbrod
et al., 1993). Despite sharing a high degree of sequence
homology, they seemed to differ to a large extent in expres-
sion titers.
An alignment of the sequences of hu4D5 and McPC6O3 Fv,
based on a structural definition for the CDRs, showed that 67
of 89 framework residues are identical in VL (75%) and 72 of
92 framework residues are identical in VH (78%). Nevertheless,
the yield of recombinantly expressed and purified McPC6O3
F(ab) was -0.2 mg per liter of bacterial culture and OD (Skerra
and PlUckthun, 1991), while the reported yield of the hu4D5
F(ab) fragment was ~50-fold higher (Carter et al., 1992).
Analysis systems were developed to investigate the fate of
the antibody proteins in vitro and in vivo. A shortened improved
FLAG epitope (Prickett et al., 1989; Knappik and PlUckthun,
1994) on the N-terminus of the heavy and/or light chain,
combined with a quantitative luminescence-based Western blot
(Ge et al., 1994), were used to quantify antibody protein, in
both the soluble and insoluble forms, produced and transported
to the periplasm of the bacteria. Correct assembly of the
protein was determined independently by antigen affinity
chromatography which does not allow either chain to bind
separately. The effect on the E.coli growth physiology was
measured by determining growth rates and the leakage of
periplasmic p-lactamase into the growth medium after
induction.
Comparison of hu4D5 and McPC603 antibody expression
The extraordinary expression levels of the hu4D5 F(ab) frag-
ment were reported for high cell density fermentation (Carter
et al, 1992), while the McPC603 fragments were mostly
studied in shake flasks (Skerra and PlUckthun, 1991; Knappik
et al., 1993). Additionally, the growth media, the expression
vectors and the E.coli strains were different in both systems.
Therefore it was not possible to compare the available data
directly or to give any statements about the reasons for the
differences in expression titers.
For these reasons it was necessary to first investigate the
antibody expression in identical E.coli host/vector systems.
We PCR-cloned the coding regions of the variable and the
constant domains of the hu4D5 F(ab) gene independently,
using the vector pAK19 as a template, into the pHJ vector
series (leading to Fv-, F(ab)- and scFv- expression vectors)
and could then compare the expression behavior of the
McPC603- and hu4D5 antibody fragments directly.
We found that in identical E.coli host/vector systems an
enormous increase in the amount of folded periplasmic protein
of hu4D5 compared with McPC6O3 was found, and this was
observed independent of whether Fv, scFv or F(ab) fragments
were studied. However, we also observed a marked physiologi-
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cal difference: cells expressing McPC603 became leaky and
eventually lysed, and major parts of the expressed molecules
were found as insoluble aggregates (see below). These unfavor-
able effects on folding and growth physiology were absent
when the cells expressed the corresponding hu4D5 fragments.
We concluded therefore that the primary sequence alone must
be responsible for the differences in both expression yield and
cell stability during expression.
Point mutations in the McPC603 antibody framework improve
its expression yield
We then wished to find out whether these effects could be
ascribed to individual amino acid substitutions between the
Table I. Mutations introduced in the McPC603 VH framework
Mutant P40A 148 V S63A AMD 17 IT V72I Q78K A87S
40 48 60 61 68 69 75 82B
HI •
H2 •
H3 • •
H4 •
H5 • • •
H6 •
H7 • • • •
H8 • • • •
H9 • • • • • •
H10 • • • • • • • •
Hll • • •
H12 • • • • • • •
Each line represents a different protein carrying the mutations indicated.
The residues are numbered according to the McPC603 VH sequence (Satow
et al., 1986). The second line gives the residue numbers according to Kabat
et at. (1991) and is provided to simplify comparison of the positions with
other antibodies.
two antibodies. After domain switching experiments had
shown that both the growth and leakiness phenotype and the
folding problems were associated with VH (A.Knappik and
A.PIUckthun, unpublished results), a number of single and
multiple mutations (Table I) were constructed and analyzed,
first in the form of the Fv fragment. We limited this analysis
to framework regions using a structural definition of the CDRs,
with a view to defining a generally useful antibody framework.
The selection of the mutations was based on a comparison of
the framework sequences of the McPC603 and hu4D5 VH
sequences, and any changes introduced during the human-
ization of 4D5, which itself appeared to improve folding
(Carter et al., 1992).
Indeed we found from this analysis that certain point
mutations improved the expression behavior of the McPC603
antibody. Surprisingly, the growth/leakiness phenotype and the
folding properties could be separated. The substitution P40A
(HI mutant; Table 1) led to a slight decrease in leakiness and
improved cell growth (with no influence on the amount of
insoluble protein), while double mutant H3 (S63A/A64D)
eliminated most of the insoluble protein yet had no effect on
cell physiology (Figure 1). The H10 mutant, containing all
eight mutations tested (Table I), showed a further improved
phenotype: the ratio of soluble to insoluble protein was identical
to H3, but the leakiness of cells during induction was much
more reduced than with the HI mutant. As a control, the Fv
fragment carrying all except the P40A mutation (HI2; Table
I) was tested and found to lead to a leaky phenotype (data not
shown). Therefore we concluded that the improved expression
behavior of mutant H10 is due to the combination of mutations
HI and H3. We tested this hypothesis by constructing the
mutant Fv fragment Hll which carried both the HI and the
H3 mutations (Table I). Indeed we found that this combination
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Fig. 1. Comparison of growth and leakiness phenomena of cells expressing various antibody Fv fragments. (A) Growth curves of cells expressing McPC603
wild-type ( • ) , P40A (O) and S63A/A64D (A) (B) Corresponding leakiness data during inducuon, given as P-lactamase activity per OD in the culture
supernatant. The symbols correspond to those in (A). (C) Comparison of growth curves of cells expressing the Fv fragments of McPC603 wild-type ( • ) , the
triple mutation P40A/S63A/A64D (V) and the hu4D5 fragment (O). (D) Corresponding P-lactamase activities in the medium. The symbols correspond to
those in (C).
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Fig. 2. Western blots showing the soluble (A) and insoluble (B) fractions of
cell extracts, prepared as described in Materials and methods, expressing the
Fv fragments of the McPC603 wild-type (a), the P40A mutation (b), the
S63A/A64D mutation (c) and the triple mutation P40A/S63A/A64D (d). The
amounts loaded on the gel were normalized to the same P-lactamase activity
and diluted by the factor indicated in the panels. A dilution of 1
corresponds to -100 \l\ of cell culture with an OD5Jo of I. The first lane
(M) shows the size marker. Since with the constructs used here the
detection of the heavy chain in Western blots is 10-fold more sensitive than
the detection of the light chain due to differences in the FLAG epitope
(Knappik and PlUckthun, 1994), only the heavy chain is visible in this type
of blot (indicated by an arrow). The band visible below the VH chain
corresponds to cross-reacting hen-egg lysozyme used to lyse the cells.
Table II. Summary of in vivo properties of the mutated Fv fragments
compared with the McPC603 wild-type Fv fragment
P40A S63A/
A64D
P40A/S63A/
A64D
Soluble (%)'
Insoluble (%)'
Increase in soluble/insoluble ratio
Functional yield (%)b
Cell stability0
Volume yield (%)d
300
100
3-fold
300
+
400
200
10
20-fold
200
±0
200
300
5
60-fold
300
1000
"Relative amounts of soluble and insoluble mature VH chain from the Fv
fragment after 3 h induction at 24°C as estimated from densitometric
scanning of Western blots (see Figure 2). The corresponding values of the
wild-type are set to 100%.
'Functional yield (normalized to equal cell densities) given as the relative
amount of Fv fragment purified from crude extracts by antigen affinity
chromatography after 3 h induction at 24°C, compared with the McPC6O3
wild-type Fv fragment set at 100%.
Stability during expression at 24°C of cells expressing mutated Fv
fragments compared with cells expressing the McPC603 wild-type Fv
fragment. See Figure 1 for details.
dYield of mutated Fv fragments per liter cell culture, purified from crude
extracts by antigen affinity chromatography after 'optimal' induction periods
at 24°C is compared with the functional yield obtained with the McPC6O3
wild-type Fv fragment after 3 h of induction at 24°C. The 'optimal'
induction period depends on die cell stability during induction and amounts
to 5 h for the fragment containing the P40A mutation, 3 h for the fragment
containing the S63A/A64D mutation and 12 h for the fragment containing
the P40A/S63A/A64D mutation
had a synergistic effect, almost completely eliminating any
insoluble protein (Figure 2 and Table II) and approaching
the favorable growth behavior of cells expressing hu4D5
(Figure 1).
The relative effect of the mutations on the in vivo folding
yields (Table II) was found to be similar in the F(ab) and scFv
fragments as in the Fv fragments, suggesting that the diversion
from the folding pathway appeared to be governed by the
folding of an individual domain. However, the effect of the
P40A mutation on the lysis phenotype was much reduced in
F(ab) and scFv fragments compared with Fv. We conclude
that the lysis phenotype is not proportional to the amount of
Fig. 3. (A) Location of the mutations in the structure of the
phosphorylcholine binding antibody McPC603 (Satow et al., 1986). (B)
Superposition of the heavy chains of McPC603 (black) and hu4D5 (grey)
(Eigenbrod et al., 1993).
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insoluble protein, and must be caused by the differential
interaction of the various proteins with one or more cellular
components during transport or folding.
Improved cell stability during induction of the expression
of Hll mutant was significant at lower growth temperatures
and was lost at 37°C, while the ratio of soluble to insoluble
protein was independent of the growth temperature (data not
shown). In contrast, cells expressing the hu4D5 Fv fragment
remained stable at all temperatures tested. Therefore, additional
crucial residues, either in the framework or in the CDRs, must
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Fig. 4. Equilibrium denaturation curves of Fv fragments [McPC603 ( • ) ,
P40A (O), S63A/A64D (A) and P4OA7S63A/A64D (V)]. The fraction
unfolded was calculated from the wavelength of the fluorescence maximum
(A j^ = 280 nm), measured as a function of the denaturant concentration.
The calculated values for m (the slope of the curve in the transition region)
and the differences in AG(H2O) are given in Table III.
be responsible for the differences in cell stability when the
expression was carried out at 37°C. To distinguish between
these two possibilities, we also grafted the CDRs of the
McPC6O3 Fv antibody on the hu4D5 framework. This chimeric
molecule consisted of the hu4D5 framework residues and the
McPC603 CDRs. However, we found no additional improve-
ments in yield and growth physiology with our assay systems
(A.Knappik, H.Bothmann, K.Bauer and A.Plllckthun, manu-
script in preparation).
We conclude therefore that the observed difference in
stability between cells grown at 37°C and expressing the
hu4D5 or the McPC603 Fv fragment containing the Hll
mutations must be due to the different CDR sequences of the
two antibodies. The mutations we found (Figure 3), however,
are sufficient to eliminate the differences between the hu4D5
and the McPC603 framework in yield and cell physiology.
In vitro analysis of the mutant Fv fragments
We next sought to establish if the effects observed in vivo
could be related to in vitro properties of the proteins. An
in vitro characterization of the wild-type and mutant Fv
fragments showed that these mutations did not increase the
thermodynamic stability of the proteins, as measured by urea-
induced fluorescence changes (Figure 4). When measuring the
folding rate of the oxidized Fv fragments (containing the
intradomain S-S bonds), a kinetic intermediate was detected by
fluorescence changes, which was formed faster than precisely
measurable by manual mixing and which slowly interconverted
50 100
time (min)
150 200
100
time (min)
150 200
50 100 150
time (min)
200
50 100
time (min)
150 200
Fig. 5. Time-course of refolding of urea-denatured Fv fragments [McPCo03 (D), P40A (O), S63A/A64D (A) and P40A/S63A/A64D (V)] of either oxidized
(A and B) or reduced (C and D) protein, monitored by fluorescence spectroscopy. (A and C) The shift of the emission peak during refolding is plotted against
the time. The fully denatured protein shows an emission maximum at 348.3 nm, while the folded protein has an emission maximum at 331.4 nm (see small
insert in A). (B and D) The amount of protein reaching a native-like state (as given in A and C) during refolding is plotted using the fluorescence intensity at
331.4 nm. See Materials and methods for details.
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to the native state. The yields and rates of the slow folding
step were again identical for all proteins examined (Figure 5A
and B). To mimic the in vivo situation more closely, the
experiment was repeated for the reduced proteins (Figure 5C
and D). This time, the kinetics of the slow step differed
dramatically between the proteins: while the McPC603 wild-
type and (less dramatically) HI mutant fragment did not fold
during the time of measurement, but rather aggregated very
rapidly, the H3 and particularly H11 mutant fragments intercon-
verted slowly into a native-like structure (Figure 5C). More-
over, the yield also followed the in vivo results (Figure 5D).
Interestingly, the synergistic effect observed in vivo with the
triple mutant fragment could also be observed in vitro. It thus
appears that a folding intermediate differs between the mutant
proteins in its tendency to aggregate.
A similar ranking of the mutant fragments could be obtained
by measuring by light scattering the rate of thermally induced
aggregation, whose time-courses were consistent with a uni-
bimolecular process when examined at different concentrations
(data not shown) but followed first-order kinetics at 1.0 \iM.
Interestingly, since the slopes of the temperature dependence
of the aggregation rate were identical for all mutants (Figure
6), the enthalpy of activation is similar for all proteins, while
the entropy of activation (the intercept in Figure 6) depends
on the nature of the amino acids at position H63 and/or H64,
but not on that at H40.
Discussion
What is the mechanistic basis of the observed differences in
expression yields? The side chain of AspH64 is exposed in
the hu4D5 Fv fragment (Eigenbrod et al, 1993) and other
antibodies which carry this amino acid, and the main chain of
McPC6O3 and hu4D5 is almost perfectly superimposable in
this region (Figure 3). A plausible explanation for the different
aggregation behavior of the mutants may thus be a greater
ordering of water around AlaH64 in the ground state, compared
with AspH64. Thus, less entropy of activation is required to
overcome the barrier for forming the crucial transition state
with increased hydrophobic surface, which leads to aggrega-
tion, since AlaH64 may start at a higher ground state level,
characterized by higher ordering of solvent. The folding
process in the bacterial periplasm mirrors the in vitro behavior
surprisingly well, suggesting that under the experimental
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Fig. 6. Thermal denaturation of wild-type and mutant antibody Fv
fragments [McPC603 ( • ) , P40A (O), S63A/A64D (A) and P40A/S63A/
A64D (V)] measured with light scattering at 400 nm as a function of
temperature.
conditions there are no molecular chaperones present in suffi-
cient amounts to efficiently prevent the aggregation reaction.
Actually, this type of mutation seems to free the protein from
the need of a chaperone.
While the mechanistic basis of the cell-stabilizing effect of
the P40A mutation (HI) is not yet clear, it acts synergistically
with the double mutation (H3) in vivo (Table II) and in vitro
(Figure 5C and D), particularly if the proteins containing either
the double (H3) or triple mutation (HI 1) are compared; thus
both mutations may act on crucial steps of the same pathway.
A speculative model consistent with the experimental data
would state that there are two crucial intermediates during the
in vivo folding pathway. The first is either itself toxic for the
cells or leads to a toxic by-product, possibly by interacting
with the transport apparatus of the cells. This effect of the
lysis mediating intermediate can be reduced by introducing
the P40A mutation in the McPC603 Fv fragment or, much
more dramatically, by introducing this mutation in the Fv
fragment which already contains the H3 mutations (Figure 1).
The second intermediate leads to aggregation of the antibody
fragments during in vivo and in vitro folding and can be
prevented by the introduction of the H3 mutations.
The folding efficiency of proteins can thus depend on single
amino acids which determine the kinetic partitioning between
folding and aggregation. In other proteins, where similar
mutations have been found (Jappelli et al., 1992; Mitraki and
King, 1992; Chrunyk et al., 1993; Deng et al., 1994), they
were also found to lie in turns of the protein. We predict that
the folding efficiency does not simply depend on a sufficient
number of equidistant surface charges in the native structure,
but that there are crucial exposed microdomains consisting of
turns which, in a folding or unfolding intermediate, become
partially detached from the protein and can, if sufficiently
hydrophobic, provide an aggregation interface. In vitro studies
with, for example, Trp synthase (London et al., 1974), carbonic
anhydrase (Cleland and Wang, 1990) and bovine growth
hormone (Brems, 1988) are all consistent with the idea that it
is an intermediate state, and neither the unfolded nor the native
state, which leads to aggregation. Brems (1988) found that
by adding helix-forming peptides from the growth hormone
sequence to the refolding mixture of this protein, the formation
of aggregates could be inhibited, suggesting that they may
bind protectively at crucial sites for die aggregation reaction.
These data are in excellent agreement with the results observed
here and support the hypothesis that specific microdomains of
a folding intermediate are susceptible to aggregation.
We suggest that a similar intermediate may be populated in
thermal denaturation and in oxidative folding, because the
mutations have a similar effect in both directions of folding.
Since the NMR signals of the backbone amide proton have
now been assigned for the Fv and single-chain Fv fragment
Table III. Summary of stability data of
Figure 4)
m (kcal/mol/M)
AAG(H2O)
(kcal/mol)
McPC603
wild-type
1.34 ± 0.08
reference
P40A
1.25 ±
0.23 ±
Fv fragments (obtained from
S63A/A64D
0.07 1.52 ± 0.10
0.2 -0.14 ± 0.2
P40A/S63A7
A64D
1.56 ±
0.13 ±
0.10
0.2
The differences of the free energy of folding AAC^HjO) compared with the
wild-type Fv fragment and the slope m in the transition region are shown.
In this measurement, the protein concentration was 0.1 \\M in all cases.
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of McPC603 (Freund et al, 1994), folding studies using NMR
may give a very detailed picture of the folding and assembly
pathway. There may thus be two solutions to the folding
problem. One, as described here, is to inhibit aggregation by
designing a charge in a crucial region likely to detach early
from the protein or to attach late in the folding. Another may
be to stabilize the interaction of this region with the rest of
the protein. This strategy might have been operative in the
disulfide mutants which stabilize T4 lysozyme against ther-
mally induced aggregation, but which do not significantly
change the overall AC of the molecule (Wetzel, 1987).
The mutations described here are of a different nature from
those described by Hurle et al. (1994). These authors identified
destabilizing mutations in VL domains which appear to be
frequent in those light chains found in amyloidosis but very
infrequent in normal light chains. The free energy of folding
was found to correlate roughly with the tendency to form
amyloid-like aggregates. In contrast, the mutations we identi-
fied do not change AG within experimental error. Furthermore,
the enhanced folding yields observed are not correlated at all
with the distribution of these amino acids. The amino acids
we replaced were not rare ones. It thus appears that there
might be a selection against unstable molecules in the animal,
but not necessarily for efficient folding. It rather seems that
the eukaryotic organism has other means to overcome these
problems.
The antibody folds after transport into the endoplasmic
reticulum and it appears to be guided by at least two chaperones,
Hsp70 (BiP) and Hsp90 (GRP94) (Melnick et al., 1994). In
addition, protein disulfide isomerase (PDI) has been shown to
be involved in this process in vivo (Roth and Pierce, 1987). It
is not yet known whether calnexin, a membrane-bound protein
in the endoplasmic reticulum presumed to be involved in
glycoprotein folding (Bergeron et al., 1994), also participates
in the folding process of the heavy chain, at least for some
subclasses. In contrast, the chaperone content of the periplasmic
space is probably far more modest, and there is no evidence
for ATP in this compartment (WUlfing and PlUckthun, 1994a,b).
Rather than trying to recreate an identical environment as in
the endoplasmic reticulum, which may be impossible, we
attempted therefore to engineer the protein such that it no
longer would be dependent on chaperones.
It is possible that, and it remains to be investigated whether,
the susceptibility of the improved variants to disulfide iso-
merase and proline-m-fra/w-isomerase overexpression has
changed. Depending on the folding conditions, PDI may
promote either folding or aggregation in vitro (Lilie et al.,
1994; Puig and Gilbert, 1994). While in the eukaryotic system
Hsp70 and Hsp90 are probably the main factors in preventing
premature aggregation, in the E.coli system it is the protein
structure itself which is of primary importance. It can thus not
be excluded that even better yields may now become possible,
after the first bottleneck of aggregation has been identified and
removed, by again increasing other catalysts in the system.
Recent impressive progress in constructing and screening
libraries containing large antibody repertoires (Winter et al.,
1994) has revealed the problem that limitations in the mainten-
ance and stability of the diversity, due to very different effects
of distinct antibody sequences on the bacterial cell physiology,
might lead to the elimination of clones. This study shows that
in the future, semi-synthetic libraries based on engineered
frameworks, but carrying the CDR variability, may overcome
this problem, facilitating equal representations of clones and
amplification and long-term maintenance of such libraries.
Since the aspects of stability, folding and physiology can
apparently be separated, such a design may now be possible.
Particularly attractive might be the combination of the
strategies described here with stabilizing disulfide mutations
(Glockshuber et al, 1990).
Moreover, it becomes apparent that mutations influencing
the aggregation of proteins during folding are most often
located in turns, at least in p"-barrel proteins. An engineering
approach as described here, as well as random mutagenesis
focused on turn regions, may overcome potential folding
problems of other recombinant proteins and, by evaluating
different types of folding mutations as described here, may
lead to a deeper insight into the mechanisms of protein folding.
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